Abstract:Neuraminidase (NA) is a pivotal surface enzyme and a key therapeutic target in combating the influenza A virus. Its evolution can lead to potential zoonotic transmission, seasonal epidemics, and the emergence of drug-resistant mutants. To gain comprehensive insights into the mutational effects and drug resistance profiles of NA, we employed a high-throughput profiling system to quantify the replication capacity of NA mutants at the single-nucleotide level in mouse lung tissues. The fitness of NA mutants is generally correlated with natural mutation occurrence and is constrained by both the requirement to maintain protein stability and NA function. Leveraging this system, we profiled the drug resistance to the three most commonly used neuraminidase inhibitors (NAIs): zanamivir, oseltamivir, and peramivir. In addition to identifying previously reported drug resistance mutations, we validated novel mutants. Notably, we identified an allosteric mutation that confers resistance to all three drugs, which may affect drug binding by interfering with the tetramerization of NA. Moreover, the fitness cost associated with drug-resistant mutations may limit their widespread dissemination. In summary, we provided a parallel characterization of NA's fitness and drug resistance landscape in an context, which may guide the rational selection of antiviral drugs for optimal therapeutic efficacy and second-generation NAI development. IMPORTANCE NA is a crucial surface antigen and drug target of influenza A virus. A comprehensive understanding of NA's mutational effect and drug resistance profiles is essential for comprehending the evolutionary constraints and making informed choices regarding drug selection to combat resistance in clinical settings. In the current study, we established an efficient deep mutational screening system in mouse lung tissues and systematically evaluated the fitness effect and drug resistance to three neuraminidase inhibitors of NA single-nucleotide mutations. The fitness of NA mutants is generally correlated with a natural mutation in the database. The fitness of NA mutants is influenced by biophysical factors such as protein stability, complex formation, and the immune response triggered by viral infection. In addition to confirming previously reported drug-resistant mutations, novel mutations were identified. Interestingly, we identified an allosteric drug-resistance mutation that is not located within the drug-binding pocket but potentially affects drug binding by interfering with NA tetramerization. The dual assessments performed in this study provide a more accurate assessment of the evolutionary potential of drug-resistant mutations and offer guidance for the rational selection of antiviral drugs.

Neuraminidase Pharmacophore Model Derived from Diverse Classes of Inhibitors.

Pharmacophore Modeling, 3D‐QSAR Studies, and In‐silico ADME Prediction of Pyrrolidine Derivatives As Neuraminidase Inhibitors

Discovery of Influenza A Virus Neuraminidase Inhibitors Using Support Vector Machine and Naïve Bayesian Models

Novel Dual‐Site‐Binding Neuraminidase Inhibitor from Virtual Screening by Pharmacophore and Molecular Dynamics Methods

Develop integration modeling approach for discovery neuraminidase inhibitors in silico based on pharmacophore and CoMSIA models

Structure-based methoxyflavone derivatives with potent inhibitory activity against various influenza neuraminidases

Virtual screening approach to identifying influenza virus neuraminidase inhibitors using molecular docking combined with machine-learning-based scoring function

Discovering Neuraminidase Inhibitors via Computational and Experimental Studies

MedChemExpress compounds prevent neuraminidase N1 via physics- and knowledge-based methods

Discovery and Characterization of a Novel Peptide Inhibitor Against Influenza Neuraminidase

Development of 3D-QSAR combination approach for discovering and analysing neuraminidase inhibitors in silico.

Discovery of novel thiophene derivatives as potent neuraminidase inhibitors

Design, synthesis, bioactivity, and DFT calculation of 2-thiazolyl-hydrazone derivatives as influenza neuraminidase inhibitors

Pharmacophore-based virtual screening, molecular docking and molecular dynamics studies for the discovery of novel neuraminidase inhibitors

Insights from modeling the 3D structure of H5N1 influenza virus neuraminidase and its binding interactions with ligands.

Binding Mechanism of H5N1 Influenza Virus Neuraminidase with Ligands and Its Implication for Drug Design

Recent advances in the structure-based design of neuraminidase inhibitors as antiinfluenza agents.

Design, synthesis and biological evaluation of sulfamethazine derivatives as potent neuraminidase inhibitors

Mechanism-Based Covalent Neuraminidase Inhibitors with Broad-Spectrum Influenza Antiviral Activity

Deep mutational scanning of influenza A virus neuraminidase facilitates the identification of drug resistance mutations in vivo .

Influenza neuraminidase operates via a nucleophilic mechanism and can be targeted by covalent inhibitors